These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1226 related items for PubMed ID: 28749535

  • 1. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 2. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
    Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.
    Cell Death Dis; 2013 Sep 19; 4(9):e810. PubMed ID: 24052078
    [Abstract] [Full Text] [Related]

  • 3. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 4. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W, Chen Y, Zhu KY, Deng H, Wu T, Wang J.
    Biol Pharm Bull; 2017 Aug 01; 40(8):1306-1313. PubMed ID: 28515374
    [Abstract] [Full Text] [Related]

  • 5. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F, Zhao Y, Li X, Tang Q, Wu J, Wu W, Hann SS.
    J Ethnopharmacol; 2019 Jul 15; 239():111928. PubMed ID: 31077779
    [Abstract] [Full Text] [Related]

  • 6. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 7. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Jul 26; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 8. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
    Xu L, Meng X, Xu N, Fu W, Tan H, Zhang L, Zhou Q, Qian J, Tu S, Li X, Lao Y, Xu H.
    Cell Death Dis; 2018 Feb 15; 9(3):262. PubMed ID: 29449529
    [Abstract] [Full Text] [Related]

  • 9. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 15; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z, Zhang SL, Hu X, Tam KY.
    Eur J Pharmacol; 2018 Nov 05; 838():41-52. PubMed ID: 30213498
    [Abstract] [Full Text] [Related]

  • 11. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
    Osude C, Lin L, Patel M, Eckburg A, Berei J, Kuckovic A, Dube N, Rastogi A, Gautam S, Smith TJ, Sreenivassappa SB, Puri N.
    Cells; 2022 May 19; 11(10):. PubMed ID: 35626731
    [Abstract] [Full Text] [Related]

  • 12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.
    Cancer Sci; 2018 Oct 19; 109(10):3183-3196. PubMed ID: 30098066
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.
    Clin Cancer Res; 2014 Aug 01; 20(15):4059-4074. PubMed ID: 24919575
    [Abstract] [Full Text] [Related]

  • 14. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
    Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP.
    J Thorac Oncol; 2009 Feb 01; 4(2):161-6. PubMed ID: 19179890
    [Abstract] [Full Text] [Related]

  • 15. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.
    J Clin Invest; 2014 Jul 01; 124(7):3003-15. PubMed ID: 24911146
    [Abstract] [Full Text] [Related]

  • 16. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
    Xu X, Liu Y, Gong Q, Ma L, Wei W, Zhao L, Luo Z.
    Cancer Chemother Pharmacol; 2024 Aug 01; 94(2):209-221. PubMed ID: 38609654
    [Abstract] [Full Text] [Related]

  • 17. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 01; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 18. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Oct 01; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
    Kim DM, Kim MJ, Moon JH, Lee EY, Hong JK, Lee S, Koh DI, Ryu YS, Kim SM, Jung SA, Shin JS, Kim J, Park YS, Hong SW, Lee SH, Jung J, Park SS, Kim DY, Kim EH, Jeong HR, Gong JH, Kim J, Chan Kim S, Yu HN, Ki SY, Kim TW, Jin DH.
    Biochem Biophys Res Commun; 2020 Jun 18; 527(1):305-310. PubMed ID: 32446385
    [Abstract] [Full Text] [Related]

  • 20. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H, Wang S, Takayama K, Harada T, Okamoto I, Iwama E, Fujii A, Ota K, Hidaka N, Kawano Y, Nakanishi Y.
    Lung Cancer; 2015 Apr 18; 88(1):1-8. PubMed ID: 25670150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.